'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
- Home Page
- What's New?
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Resources
- Contact Us
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Clinical Trials
- Cancer Biomarkers
- Lung Cancer
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- VEGF in lung cancer
- Prevalence of VEGF
- VEGF and prognosis
- Malignant pleural effusion
- Survival
- Summary
- Evidence of VEGF expression
- VEGF and disease progression
- Pancreatic Cancer
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Lung Cancer
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Receptor-Mediated Endocytosis
- Anti-PDL1 (MPDL3280A)
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- HER Signaling
- Anti-PDL1 (MPDL3280A)
- Inhibition of HER2 dimerization
- Glossary
- Slide decks and videos
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Gastric Cancer
- Antibody-Drug conjugates
Share
HER1 Epidermal Growth Factor Receptor (EGFR) Overview
— Herbst RS and Bunn PA Jr, Clin Cancer Res, 20031
These findings indicate that there is an important role for aberrant EGFR signaling in the development and progression of various human tumors. In addition, they provide a strong rationale for EGFR-TK as a target molecule for the development of new cancer therapies.
HER1, also known as the epidermal growth factor receptor (EGFR), drives the development of multiple solid tumor types. This section of ResearchHERPathways.com focuses on HER1/EGFR signaling, how HER1/EGFR is measured, its prognostic value, and its relationship with specific tumor types. Click on the links below to learn more.